Related Experiment Video
Updated: Aug 9, 2026
Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits
Published on: June 2, 2019
Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor
H Ishii1, M R Jirousek, D Koya
1Research Division, Joslin Diabetes Center, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA.
Abstract:
The vascular complications of diabetes mellitus have been correlated with enhanced activation of protein kinase C (PKC). LY333531, a specific inhibitor of the beta isoform of PKC, was synthesized and was shown to be a competitive reversible inhibitor of PKC beta 1 and beta 2, with a half-maximal inhibitory constant of approximately 5 nM; this value was one-fiftieth of that for other PKC isoenzymes and one-thousandth of that for non-PKC kinases. When administered orally, LY333531 ameliorated the glomerular filtration rate, albumin excretion rate, and retinal circulation in diabetic rats in a dose-responsive manner, in parallel with its inhibition of PKC activities.
Insights
Diabetic vascular complications linked to protein kinase C (PKC) activation. A specific PKC inhibitor, LY333531, improved kidney function and retinal circulation in diabetic rats by blocking PKC.
Area of Science:
- Biochemistry
- Pharmacology
- Diabetology
Background:
- Vascular complications in diabetes mellitus are associated with increased protein kinase C (PKC) activity.
- Protein kinase C (PKC) plays a critical role in the pathogenesis of diabetic vascular disease.
Discussion:
- LY333531, a selective inhibitor of the PKC-beta isoform, demonstrates potent and reversible inhibition of PKC beta 1 and beta 2.
- The inhibitor exhibits high specificity, with a half-maximal inhibitory constant (Ki) of approximately 5 nM for PKC beta isoforms, significantly lower than for other PKC isoenzymes and non-PKC kinases.
Key Insights:
- Oral administration of LY333531 in diabetic rats led to dose-dependent improvements in glomerular filtration rate and albumin excretion rate.
- The study observed amelioration of retinal circulation in diabetic rats treated with LY333531, correlating with reduced PKC activity.
Outlook:
- LY333531 shows therapeutic potential for managing diabetic vascular complications.
- Further research may explore the clinical efficacy and safety of selective PKC-beta inhibitors in diabetic patients.
